Compare AGMB & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGMB | CBLL |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Belgium | United States |
| Employees | N/A | 280 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.9M | 750.1M |
| IPO Year | N/A | N/A |
| Metric | AGMB | CBLL |
|---|---|---|
| Price | $12.86 | $18.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $32.00 | $24.67 |
| AVG Volume (30 Days) | 115.4K | ★ 281.3K |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.57 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $10.01 |
| 52 Week High | $17.45 | $24.33 |
| Indicator | AGMB | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 47.50 |
| Support Level | N/A | $18.78 |
| Resistance Level | $15.05 | $19.88 |
| Average True Range (ATR) | 1.33 | 0.76 |
| MACD | -0.16 | 0.13 |
| Stochastic Oscillator | 51.92 | 52.86 |
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.